BlueScope left investors disappointed this morning with a 64% lower net profit
Nick Sundich, February 20, 2023
Of this morning’s 1HY23 results, Bluescope (ASX:BSL) was the one that left investors the most disappointed, if the ~7% share price decline is any guide. The company’s net profit and EBIT both declined by over 60%, missing analysts expectations.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Bluescope’s EBIT and net profit fell by over 60%
1HY23 was a difficult market for steel with weather related disruptions in building and construction activity.
Although Bluescope’s revenue was only down 1.2% from 12 months ago (at $9.3bn), the company’s EBIT and net profit came in at 60% lower than 12 months ago – at $834.4m and $598.8m respectively. The company’s ROIC also fell from 43.7% to 23.4%.
On a more positive note, the company’s net cash grew $367m to $606m and its free cash flow (operaitng cash flow less capex) was up $63m to $751m. Its interim dividend was unchanged at 25cps, representing a 2.7% yield on an annualised basis.
Shares fell by over 7% in this morning’s trade, the most of any company releasing 1HY23 results.
Bluescope (ASX:BSL) share price chart, log scale (Source: TradingView)
Bluescope says the long-term outlook remains positive
Despite the negative results, Bluescope told shareholders it was well positioned for the long-term.
The company said the global green revolution was driving demand for steel as a critical input towards particular types of infrastructure, particularly renewable energy and e-commerce infrastructure.
It also noted consolidation and rationalisation in the US steel industry and a focus on emissions reduction by China’s steel industry supported supply-side discipline.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Kamala Harris stocks: If Joe Biden’s VP wins the White House in 2024, which stocks will win?
With the US Presidential election now certain to be a Kamala Harris v Donald Trump showdown, we’ve looked at so-called…
South32 (ASX:S32): Is it the dark horse amongst ASX 200 miners or have cyclones and commodity prices hit it too hard?
South32 (ASX:S32) began life as a spinoff from BHP back in 2015, capitalised at $9bn. In mid-2024, it is capped…
Here’s why drug reimbursement is so important for ASX healthcare stocks
Let’s take a look at the concept of drug reimbursement, something that is crucial for ASX healthcare stocks looking to…